Selected article for: "acute respiratory syndrome and lung pulmonary hypertension"
Author: Shenoy, Vinayak; Ferreira, Anderson J.; Katovich, Michael; Raizada, Mohan K.
Title: Angiotensin-Converting Enzyme 2/Angiotensin-(1-7)/Mas Receptor Axis: Emerging Pharmacological Target for Pulmonary Diseases
  • Cord-id: z6ddajd6
  • Document date: 2015_4_24
    • ID: z6ddajd6
    Snippet: Experimental and clinical evidence supports an active role of the renin–angiotensin system (RAS) in the pathogenesis and progression of lung diseases. Angiotensin II (Ang II), a key vasoactive peptide of the RAS, has been implicated in pulmonary disorders such as pulmonary arterial hypertension, lung fibrosis, chronic obstructive pulmonary disease, and acute respiratory distress syndrome. Over the past few years, the classical concept of the RAS has undergone substantial changes to include sev
    Document: Experimental and clinical evidence supports an active role of the renin–angiotensin system (RAS) in the pathogenesis and progression of lung diseases. Angiotensin II (Ang II), a key vasoactive peptide of the RAS, has been implicated in pulmonary disorders such as pulmonary arterial hypertension, lung fibrosis, chronic obstructive pulmonary disease, and acute respiratory distress syndrome. Over the past few years, the classical concept of the RAS has undergone substantial changes to include several new active components. Among them, the identification of angiotensin-converting enzyme 2 (ACE2), its metabolic product angiotensin-(1-7) (Ang-(1-7)), and the Mas receptor has been of biological significance since these components form a counterregulatory axis (ACE2/Ang-(1-7)/Mas) that opposes the detrimental actions of Ang II. In this chapter, we will discuss the role of the ACE2/Ang-(1-7)/Mas axis in lung diseases and describe novel therapeutic approaches to activate this axis for the treatment of pulmonary disorders.

    Search related documents:
    Co phrase search for related documents
    • ace inhibitor and acei ace inhibitor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • ace inhibitor and acute ards respiratory distress syndrome: 1, 2, 3, 4
    • ace inhibitor and acute lung injury: 1, 2, 3, 4
    • ace inhibitor and acute lung injury beneficial effect: 1
    • ace inhibitor and lung collagen: 1
    • ace inhibitor and lung collagen accumulation: 1
    • ace inhibitor and lung disease: 1
    • acei ace inhibitor and acute lung injury: 1, 2
    • acei ace inhibitor and acute lung injury beneficial effect: 1
    • acquire respiratory syndrome and acute ards respiratory distress syndrome: 1
    • active involvement and acute ards respiratory distress syndrome: 1
    • active involvement and lung disease: 1
    • acute ards respiratory distress syndrome and lung collagen: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute lung injury and lung collagen: 1, 2, 3, 4, 5, 6
    • acute lung injury and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute lung injury severe form and lung collagen: 1
    • acute lung injury severe form and lung disease: 1, 2
    • acute lung injury treatment and lung collagen: 1, 2